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Available online 6 February 2016Cardiovascular disease (CVD) is now the most prevalent and debilitating disease affecting the Chinese popula-
tion, we aim to provide the latest nationwide estimates on the prevalence of main CVD risk factors. Using a com-
plex, multistage, probability sampling design, a cross-sectional study was performed in a nationally
representative sample of 17,708 adults aged 45 years and older from 28 provinces in 2011–2012. Overall, the
age-standardized prevalence of subjects having 1, 2, 3, or ≥4 of the 5 risk factors was 30.5%, 29.8%, 19.7%, and
7.4%, respectively. The prevalence of being dyslipidemia, hypertension, diabetes, current smoking, and over-
weight or obese was 62.6%, 39.9%, 18.7%, 27.5%, and 32.6%, respectively. Clustering of CVD risk factors was a
high health burden in the Chinese middle aged and elderly population. These results underscore the need for
strategies aimed at the prevention, detection, and treatment of cardiovascular risk factors to reduce morbidity
and mortality from cardiovascular disease.
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China1. Introduction
Cardiovascular disease (CVD) is the leading cause of death globally,
accounting for 30% of deaths and resulted in 17.5 million deaths [1,2],
which is predicted to increase to approximately 25 million deaths by
2020 [3]. Modiﬁable risk factors for CVD, mainly including hypertension,
smoking, abdominal obesity, abnormal lipids, and diabetes mellitus, are
themajor contributors to cardiovascular morbidity andmortality [4], ac-
counting for more than 90% of all myocardial infarctions [5]. Total global
mortality estimates [6–8] showed that the top 3 causes of death in indus-
trialized countries are hypertension, tobacco use, and high Body-mass
index (BMI)—all high-proﬁle risk factors for CVD. Furthermore, similar
trends are now emerging in economically developing countries as the
population aging and lifestyles in lower- and middle-income countries
become more akin to those of wealthier nations [9,10].
And according to the previous surveys, included the 2000–2001
International Collaborative Study of Cardiovascular Disease in ASIA
(InterASIA) [11] and the 2007–08 China National Diabetes and
Metabolic Disorders Study [12], CVD and main CVD risk factors were
also the most prevalent and debilitating disease affecting the Chinese
population. China is currently experiencing rapid economic, social and
cultural changes, including accelerated pace of nutrition transition and
changes in people's lifestyles that may contribute to greatly increased
burden of CVD. Understanding the prevalence of CVD risk factors in theen access article under the CC BY-NCnational level is important to develop the effective programs and strate-
gies to lower the population burden of illness due to CVD. However, little
is known about the recent prevalence of CVD risk factors from large-scale
national representative surveys in China within the recent 5 years.
Therefore, the 2011–12 China Health and Retirement Longitudinal
Study (CHARLS) is to provide the most recent nationwide estimates of
CVD risk factors.2. Methods
To ensure the adoption of best practices and international compara-
bility of results, CHARLS was harmonized with leading international
research studies in the U.S. Health and Retirement Study (HRS) model.
The Medical Ethics Committee of Peking University granted the current
study exemption from review and written informed consent was
obtained from all participants prior to data collection.
The detailed sampling design has been published previously [13,14].
Brieﬂy, the CHARLS used multistage probability sampling method to
select a representative of people aged 45 and over in China. In the ﬁrst
stage, all county-level units were stratiﬁed by region and within region
by urban districts or rural counties (The urban–rural deﬁnition here and
thereafter is based on the China National Bureau of Statistics deﬁnition
where primary sampling units are deﬁned as urban if they are located
in a city, suburb of a city, a town, suburb of a town, or other special
areas where nonfarm employment constitutes at least 70% of the work
force, such as a special economic zone and state-owned farm-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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150 county-level units within 28 provinces were randomly selected
with a probability-proportional-to-size (PPS) sampling technique. In
the second stage, neighborhoods (shequ or juweihui) in urban areas
and administrative villages (cun) in rural areas were used as primary
sampling units (PSUs), which were the lowest level of government
organization; and 3 PSUs within each county-level unit were selected
using PPS sampling. In the third stage, all of the dwellings in each
selected primary sampling unit were selected from the frame that
constructed based on maps prepared by a mapping/listing software
named CHARLS-GIS on Google Earth maps with the support of local
informants. Finally, one resident aged 45 years in each sampled
household within each PSU was randomly selected as a participant in
the survey. If the chosen household had more than one age-eligible
member, one such member was randomly selected, and his or her
spouse who was also aged 45 years was also included in the survey.
All stages of the sampling were conducted by a computer to avoid
human manipulation.
The CHARLS is a nationally representative longitudinal survey of
persons in China 45 years of age or older, obtaining information on
demographic background, health status and functioning, health care
and insurance, work, retirement and pension. The interviewers were
trained at Peking University by CHARLS staff members, and the inter-
views took place in respondents' households using a face-to-face
computer-assisted personal interview (CAPI) technology. The inter-
viewers also carried equipment to measure the health functioning and
performance in respondents' homes. After completing the household
interviews, respondentswere invited to a local ofﬁce of theChinaCenter
for Disease Prevention and Control (CDC) or to township hospitals,
where trained nurses drew 8-mL samples of fasting blood. The
CHARLS survey was conducted from May 2011 to March 2012 in
China 28 provinces. Overall, out of the total estimated number
(12,740) of age-eligible households, CAPI interviews were conducted
on a total of 17,708 individuals aged 45 years living in 10,287 house-
holds with the overall response rate of 80%. Among all study
participants, 13,978 individuals (78.9%) provided anthropometric and
physical performance measures. The target sample for taking blood
samples was the entire group of 17,708 main respondents and spouses
from themain CHARLS national baseline. Out of this, we collected blood
samples for 11,847 individuals, a response rate of 67% (women 69%
versus men 65%) [13–15].
Data collectionwas conducted in examination centers at local health
stations or community clinics in the participants' residential area by
trained staff according to a standardprotocol [14]. Heightwasmeasured
using the SecaTM213 stadiometer (Manufacturer: Seca Trading Co.,
LTD., Hangzhou, China). The respondent removes the shoes and stands
erect on the ﬂoor board of the stadiometer with the back to the vertical
backboard of the stadiometer. Weight was measured by the OmronTM
HN-286 scale (Manufacturer: Krell Precision Co. LTD., Yangzhou,
China). Respondents were instructed to remove their shoes, any bulky
clothing and heavy objects from their pockets. An appropriate spot to
place the scale, preferably a non-carpeted area, was identiﬁed. Blood
pressure was measured on the respondent's left arm three times at
45-s intervals by an Omron™ HEM-7112 Monitor (Manufacturer:
Omron Co., LTD., Dalian, China). Respondents were instructed to sit
down with both feet on the ﬂoor and their left arm comfortably
supported with the palm facing up. Respondents were asked to roll
their sleeve up unless they had on a short sleeve shirt or a thin shirt.
The cuff was adjusted to the respondent's arm ensuring that it made
direct contact with the skin, the bottom of the cuff was approximately
half an inch above the elbow and the air tube ran down the middle of
the respondent's arm.
Three tubes of overnight fasting blood specimens were collected
from each respondent by medically-trained staff from the China CDC
at centralized locations, based on a standard protocol [14,15]. First, a
2 mL tube of blood, was used for a complete blood count (CBC) test,which was performed at county CDC stations or town/village health
centers. Second, a 4 mL tube of whole blood was processed and divided
into plasma and buffy coat within the same timeframe as the CBC
measurement (the CBC was measured within 141 min of collection
and the median time from collection to CBC assay was 97 min) and
during shipment at 4 °C. After that, the plasma was stored in three
0.5 mL cryovials and the buffy coat in a separate cryovial, which were
immediately stored frozen at −20 °C and then transported to the
China CDC in Beijing within 2 weeks where they were placed at
−80 °C in a deep freezer until an assay at a CMU laboratory. Finally, a
2 mL tube of whole blood that collected for the HbA1c assay was stored
immediately and during shipment at 4 °C, and then transported to the
Chinese CDC in Beijing within two weeks, where it was placed in a
deep freezer and stored at−80 °C for the HbA1c assay.
The studymeasured glucose, glycosylated hemoglobin (HbA1c), and
a lipid panel (total, HDL, LDL cholesterol, and triglycerides) from frozen
plasma or whole blood samples, which assays were performed at the
Youanmen Center for Clinical Laboratory of Capital Medical University
that has regular external quality assessment organized by the Chinese
Ministry of Health. The assay method of HbA1c, glucose and a lipid
panel (total, HDL, LDL cholesterol, and triglycerides) was Boronate
afﬁnity HPLC, and Enzymatic colormetric test, respectively; the
coefﬁcient of variation (CV) of within-assay was 1.90%, 0.90%, and
0.80%, 1.00%, 0.70%, 1.50%, respectively; the CV of between-assay was
2.10%, 1.80%, and 1.70%, 1.30%, 1.20%, 1.80%, respectively; the detection
limits were 0–40%, 2-450 mg/dL, and 3-800 mg/dL, 3-120 mg/dL, 3-
400 mg/dL, 4-1000 mg/dL, respectively [15].
Body-mass index (BMI)was calculated asweight (kg) divided by the
square of height (m). A BMI of 25–30 kg/m2was deﬁned as overweight,
and a BMI of ≥30 kg/m2 was considered obese [16]. Diabetes was
deﬁned as fasting plasma glucose ≥7.0 mmol/L (126 mg/dL) or HbA1c
concentration of 6.5% ormore or a self-reported insulin or oral hypogly-
cemic treatment for diabetes [17]. Hypertension was deﬁned as the
mean systolic blood pressure (SBP) ≥140 mm Hg and/or the mean
diastolic blood pressure (DBP) ≥90mmHg and/or self-reported current
treatment for hypertension with antihypertensive medication [18].
Dyslipidemia was deﬁned as a total cholesterol concentration
≥200 mg/dL (5.2 mmol/L), or serum triglyceride (TG) level of
≥150 mg/dL (1.7 mmol/L), or low-density lipoprotein cholesterol
(LDL-C) of ≥130 mg/dL (3.4 mmol/L), or high-density lipoprotein
cholesterol (HDL-C) level of b35 mg/dL (0.9 mmol/L) in males, or
HDL-C level of b40 mg/dL (1.0 mmol/L) in females, or self-reported
current treatment with cholesterol-lowering medication. Current
smoking was deﬁned as having smoked at least 100 cigarettes in one's
lifetime and currently smoking cigarettes.
Our studywas designed to provide accurate estimates of prevalence of
major CVD risk factors according to age, sex, urban or rural residence. All
calculationswereweighted to represent the overall Chinese adult popula-
tion aged 45 years or older on the basis of 2010 China population census
data [19]. Weight coefﬁcients were derived from the China population
census data, the complex survey design and the non-response rate of
the current survey to obtain national estimates; and for the analysis of
individual biomarkers, a different set of weights were needed because
just over 20% did not get biomarkers taken, sowe did the same type of in-
verse probability weighting adjustment [15,20]. The age-standardized
prevalences were also calculated with the use of data on the population
distribution in China in 2010 [19]. Standard errors were calculated with
the Taylor-linearization method appropriate to the complex survey
design. The PROC SURVEYFREQ procedure was applied to obtain the
prevalence ofmajor CVD risk factors overall andwithin subgroups. Differ-
ences of categorical and continuous variables were tested with PROC
SURVEYLOGISTIC and PROC SURVEYREGwith adjustment for age, respec-
tively, and the PROC SURVEYLOGISTICS was applied to test for trends
across subgroups. P-values were two-sided and P-values b 0.05 were
considered signiﬁcant. All data analyses involved use of the SAS system,
version 9.1 (SAS Institute Inc.).
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Characteristics of the study participants are shown in Table 1. There
were signiﬁcant differences between men and women participants.
The age-standardized prevalence of classical CVD risk factors
including dyslipidemia, hypertension, diabetes, current smoking, and
overweight or obese was 62.6%, 39.9%, 18.7%, 27.5%, and 32.6%, respec-
tively (Table 2). The prevalences of dyslipidemia and overweight or
obese were both higher in women than in men (both P b 0.0001),
whereas the prevalence of smoking was higher in men than in women
(P b 0.0001). Dyslipidemia, hypertension, and overweight or obese
among men (P b 0.0001, P= 0.0102 and P b 0.0001, respectively), and
hypertension, diabetes and overweight or obese among women (P =
0.0234, P = 0.0205 and P = 0.0003, respectively) were more living in
urban areas compared with in rural areas. Conversely, current smoking
wasmore common in rural man residents of China comparedwith their
urban counterparts (P = 0.0076). Among both gender, hypertension
prevalence increased with age (P for trend = 0.0318 for men, P =
0.0006 for women), whereas overweight decreased with age (P for
trend b 0.0001 for men, P=0.0003 for women). Amongmen, dyslipid-
emia and current smoking decreased with age (P for trend=0.0087 for
dyslipidemia; P for trendb 0.0001 for current smoking). Amongwomen,
diabetes increased with age (P for trend b 0.0001); whereas dyslipid-
emia (P for trend = 0.0005) and current smoking (P for trend =
0.0015) were higher among subjects with older age until 75 years of
age, when the prevalence began to lower.
Overall, only 12.6% of Chinese did not have any of CVD risk factors,
and the prevalence of subjects having 1, 2, 3, or ≥4 of the 5 risk factors
was 30.5%, 29.8%, 19.7%, and 7.4%, respectively (Table 3). The proportion
of males who had ≥1, ≥2, ≥3 and ≥4 CVD risk factors was signiﬁcantly
higher than that of females (all P b 0.001). Also, the age-standardized
prevalence of subjects having ≥2, ≥3 and ≥4 CVD risk factorswas higher
among urban residents compared with rural residents in both gender,
respectively (each P b 0.001, except P= 0.0142 for ≥2 and P= 0.0011
for ≥4 CVD risk factors among men). The prevalence of subjects having
≥1, ≥2, ≥3 and ≥4 CVD risk factors was higher at older ages until
75 years of age among women, when the prevalence began to lower
(each P for trend b 0.001, except P= 0.0032 for ≥3 CVD risk factors).
4. Discussion
This nationwide survey, conducted a cross-sectional survey in a
large representative sample speciﬁcally involving the Chinese middle
aged and elderly population, provides the latest and reliable nationwide
estimates on the prevalence of theCVD risk factors. To avoid introducing
bias during the estimation, standard protocols [14,15] of the measure-
ment along with strict training processes for data collection were
used. In this national representative sample of Chinese adults, theTable 1
Descriptive characteristics for all participants stratiﬁed by gender.
Characteristic Men
Mean age (95% CI)—yr 60.1(59.9, 6
High school or higher level of education (95% CI)—% 40.3(39.0, 4
Urban residence (95% CI)—% 35.6(34.3, 3
Cigarette smoking (95% CI)—% 54.7(53.4, 5
Mean fasting glucose (95% CI)—mg/dL 110.5(109.6
Glycated hemoglobin (95% CI)—% 5.2(5.2, 5.
Body-mass index (95% CI)—kg/m2 23.0(22.9, 2
Mean waist circumference (95% CI)—cm 84.0(83.7, 8
Mean systolic blood pressure (95% CI)—mm Hg 131.1(130.4
Mean diastolic blood pressure (95% CI)—mm Hg 76.3(76.0, 7
Triglycerides (95% CI)—mg/dL 130.0(126.9
Mean HDL cholesterol (95% CI)—mg/dL 50.4(50.0, 5
Mean LDL cholesterol (95% CI)—mg/dL 111.8(110.8
Total cholesterol (95% CI)—mg/dL 187.6(186.6
Data are mean (95% CI) or percentage (95% CI).prevalence of persons with dyslipidemia, hypertension, diabetes, cur-
rent smoking, and overweight or obese was 62.6%, 39.9%, 18.7%, 27.5%,
and 32.6%, representing 277.5, 176.9, 82.8, 122.0 and 144.4 million Chi-
nese adults aged 45 years or older, respectively. And the prevalence of
one subject having 1, 2, 3, or ≥4 of the 5 CVD risk factors was 30.5%,
29.8%, 19.7%, and 7.4%, representing approximately 135.1, 132.3, 87.4
and 332.8 million Chinese adults aged 45 years or older, respectively.
Several previous studies [11,12] have documented the prevalence of
the CVD risk factors in China. The International Collaborative Study of
Cardiovascular Disease in Asia (InterAsia) [11], a cross-sectional survey
of a nationally representative sample (n = 14,690) among Chinese
adults aged 35 to 74 years conducted during 2000 to 2001, showed
that 80.5%, 45.9%, and 17.2% of Chinese adults had 1, 2, and 3modiﬁable
CVD risk factors (dyslipidemia, hypertension, diabetes, cigarette
smoking, and overweight), respectively. The 2007–2008 China National
Diabetes and Metabolic Disorders Study [12], included a nationally
representative sample of 46,239 adults age 20 years or older, showed
the prevalence of one subject having 1, 2, 3, or ≥4 of the 5 deﬁned risk
factors (overweight or obese, hypertension, cigarette smoking, dyslipid-
emia, or hyperglycemia) was 31.17, 27.38, 17.76, and 10.19%, respec-
tively. Although our results cannot directly compare with those
surveys because of the differences in diagnostic criteria of diabetes,
which may slightly increase the prevalence of diabetes, but keeping
these cautions in mind and comparing with prevalence in the corre-
sponding age group, the prevalence of subjects having ≥1, ≥2, and ≥3
modiﬁable CVD risk factors rapidly increased in 2000–2012. Compare
with the 2000–2001 InterAsia [11], the prevalence of overweight and
obesity, hypertension, lipid disorders, and diabetes in the corresponding
age group has begun to increase, the growth of diabetes prevalencewas
the largest (increased nearly 11–12 percentage point), followed by the
dyslipidemia (6–7 percentage point), overweight (5–6 percentage
point) and hypertension (2–3 percentage point), whereas current
smoking decreased about 3–4 percentage point. These results also
correspond to the prevalence of growth in total CVD diseases in our
study (results not shown) compared with the 2007 study [12]. The
rapid aging of the population, urbanization, and consequential changes
in lifestyle and diet, has probably contributed to the rapid increase in
the prevalence of CVD risk factors in the Chinese population [24]. Taking
into account the large number of middle aged and elderly population
alongwith the potential for amajor epidemic of CVD risk factors-related
complications [1,21–23], it implies a very serious public health problem
if there is no an effective intervention.
In America, data from the National Health and Nutrition Examina-
tion Survey (NHANES) from 1999 to 2000 [11] indicated that the age-
standardized prevalence of subjects having ≥1, ≥2, and ≥3 CVD risk
factors was 93.1%, 73.0%, and 35.9% for 35–74 year old adults,
respectively. And data from the landmark Hispanic Community Health
Study/Study of Latinos (HCHS/SOL) [25], involved 15,079 participantsWomen P value
0.4) 59.1(58.8, 59.3) b.0001
1.6) 22.4(21.4, 23.5) b.0001
6.8) 37.3(36.0, 38.5) 0.0412
6.0) 6.1(5.5, 6.7) b.0001
, 111.5) 110.5(109.5, 111.4) 0.7591
3) 5.3(5.3, 5.3) 0.0004
3.1) 24.0(23.9, 24.1) b.0001
4.4) 84.7(84.4, 85.1) 0.0081
, 131.7) 131.7(131.0, 132.4) 0.4024
6.7) 75.5(75.2, 75.8) 0.0034
, 133.2) 139.4(136.8, 141.9) b.0001
0.8) 51.3(51.0, 51.7) 0.0073
, 112.7) 120.2(119.3, 121.1) b.0001
, 188.6) 198.3(197.3, 199.3) b.0001
Table 2
Age-standardized or age-speciﬁc prevalence of CVD risk factors among China adult population.
Dyslipidemiaa Hypertensionb Diabetesc Current smoking Overweightd
Total 62.6(60.5,64.7) 39.9(37.7,42.1) 18.7(16.7,20.7) 27.5(25.1,29.9) 32.6(30.4,34.7)
Sex
Men 58.9(55.8,62.1) 39.0(35.8,42.1) 18.8(16.3,21.2) 50.8(46.4,55.3) 27.4(24.8,29.9)
Women 66.3(64.2,68.3) 40.8(38.6,43.0) 18.7(16.6,20.8) 5.4(3.9,6.8) 37.4(34.7,40.0)
Urbanization
Urban 66.4(63.4,69.3) 44.2(40.3,48.2) 20.9(18.0,23.8) 24.3(20.3,28.3) 39.7(36.8,42.7)
Rural 59.1(57.1,61.1) 36.5(34.1,38.9) 16.6(13.9,19.2) 30.6(29.0,32.3) 26.8(24.8,28.8)
Age (y)
45–54 60.5(57.9,63.0) 28.2(25.7,30.6) 14.8(12.2,17.3) 26.8(23.9,29.8) 36.8(34.2,39.3)
55–64 65.5(63.1,68.0) 41.9(38.5,45.4) 20.3(17.4,23.3) 32.5(29.3,35.8) 31.6(28.7,34.5)
65–74 64.2(60.1,68.3) 50.0(44.3,55.7) 19.5(16.4,22.7) 25.9(22.6,29.2) 30.1(22.5,37.7)
75– 59.7(55.3,64.1) 65.2(60.0,70.5) 28.3(17.3,39.3) 17.4(13.3,21.5) 22.5(17.0,28.1)
Men
45–54 60.5(55.7,65.4) 28.4(24.2,32.6) 15.2(12.2,18.3) 52.7(46.4,58.9) 31.9(27.0,36.8)
55–64 60.9(56.6,65.2) 42.5(36.4,48.5) 19.0(15.6,22.4) 58.6(54.2,63.0) 25.9(22.0,29.8)
65–74 55.9(50.9,60.8) 45.5(40.2,50.8) 17.3(13.9,20.7) 44.1(38.8,49.4) 25.4(17.5,33.2)
75– 51.0(44.3,57.6) 60.7(53.5,67.9) 35.1(15.2,55.0) 30.2(19.4,40.9) 16.6(9.6,23.6)
Urban 65.3(60.6,70.0) 44.9(38.6,51.30) 20.8(17.2,24.5) 44.9(37.9,51.9) 35.3(30.9,39.7)
Rural 52.9(50.5,55.3) 34.4(31.7,37.1) 16.6(13.7,19.5) 56.7(54.2,59.2) 21.3(19.0,23.5)
Women
45–54 60.4(57.4,63.5) 28.0(24.6,31.4) 14.4(11.6,17.1) 3.8(2.3,5.2) 40.8(38.2,43.5)
55–64 70.1(67.5,72.8) 41.4(38.5,44.3) 21.7(17.5,25.9) 6.0(4.4,7.7) 37.3(34.3,40.3)
65–74 72.5(68.5,76.6) 54.6(47.6,61.5) 21.8(17.5,26.1) 7.9(5.5,10.3) 34.9(26.8,43.0)
75– 67.7(61.6,73.9) 68.8(62.5,75.1) 22.1(15.8,28.3) 5.8(3.5,8.1) 27.1(20.1,34.2)
Urban 67.5(64.6,70.4) 43.7(40.4,46.9) 20.9(17.9,23.9) 5.0(3.2,6.9) 43.7(39.7,47.6)
Rural 65.1(62.7,67.4) 38.5(35.7,41.3) 16.6(13.9, 19.3) 5.7(3.9,7.5) 32.0(29.6,34.4)
Data are adjusted prevalence (%; 95% CI).
a Total cholesterol ≥ 200mg/dL (5.2 mmol/L), serum triglycerides ≥ 150mg/dL (1.7mmol/L), LDL cholesterol ≥ 130mg/dL (3.4mmol/L), or HDL cholesterol ≥ 35mg/dL (0.9mmol/L) in
males, or ≥40 mg/dL (1.0 mmol/L)in females, and/or current cholesterol-lowering medication use.
b SBP ≥ 140 mm Hg and/or DBP ≥ 90 mm Hg and/or current antihypertensive medication use.
c Fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL) or HbA1c concentration of 6.5% or more and/or current antidiabetes medication use.
d Body-mass index ≥ 25 kg/m2.
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of men, and 70%, 40%, and 17% of women had an adverse level of
subjects having ≥1, ≥2, and ≥3 CVD risk factors. Although our study
may slightly underestimate the actual prevalence of diabetes becauseTable 3
Age-standardized or age-speciﬁc prevalence of number of adverse CVD risk factorsa in the Chin
0 Risk factor 1 Risk factor
Total 12.6(11.4,13.7) 30.5(29.0,32.0)
Sex
Men 8.2(7.0,9.4) 30.7(27.9,33.6)
Women 16.4(14.6,18.3) 30.4(27.9,32.9)
Urban 11.8(9.7,13.8) 26.8(24.4,29.2)
Rural 13.2(11.9,14.4) 33.5(31.9,35.1)
Age (y)
45–54 15.1(13.0,17.2) 34.4(32.0,36.7)
55–64 11.2(9.8,12.6) 27.7(25.6,29.7)
65–74 10.2(8.0,12.4) 26.6(23.2,30.0)
75– 10.4(7.4,13.3) 29.7(23.4,36.0)
Men
45–54 7.6(5.5,9.7) 35.0(28.5,41.6)
55–64 7.3(5.7,8.9) 25.9(22.5,29.3)
65–74 9.7(7.0,12.3) 28.4(24.1,32.6)
75– 10.7(6.3,12.9) 32.1(23.6,40.6)
Urban 6.8(4.9,8.7) 28.4(22.8,34.0)
Rural 9.2(7.6,10.7) 32.6(30.2,35.0)
Women
45–54 21.2(17.4,25.0) 33.9(29.5,38.3)
55–64 15.1(13.1,17.2) 29.5(27.1,31.8)
65–74 10.7(7.7,13.7) 24.8(20.8,28.8)
75– 10.1(5.7,14.6) 27.9(21.7,34.1)
Urban 16.0(12.6,19.3) 25.6(21.2,30.0)
Rural 16.8(15.0,18.7) 34.4(32.3,36.5)
Data are adjusted prevalence (%; 95% CI).
a Risk factors include dyslipidemia (Total cholesterol ≥ 200 mg/dL [5.2 mmol/L], serum trigl
cholesterol ≥ 35mg/dL [0.9mmol/L] inmales, or ≥40mg/dL [1.0mmol/L] in females, and/or cur
90 mm Hg and/or current antihypertensive medication use), diabetes (Fasting plasma gluc
antidiabetes medication use), current smoking, and overweight (Body-mass index ≥ 25 kg/m2of the differences in diagnostic criteria, but keeping these cautions in
mind and compare with these studies in the prevalence of the
corresponding age group, the prevalence of subjects having ≥3 CVD
risk factors in China may be much less than the prevalence in the U.S.,a adult population.
2 Risk factor 3 Risk factor ≥4 Risk factor
29.8(28.7,31.0) 19.7(18.0,21.4) 7.4(6.4,8.3)
30.3(28.6,32.0) 21.0(17.9,24.0) 9.8(8.3,11.4)
29.4(28.0,30.9) 18.6(16.6,20.5) 5.3(4.3,6.2)
28.7(26.7,30.7) 23.3(20.0,26.5) 9.5(7.6,11.4)
30.7(29.5,32.0) 16.9(15.6,18.2) 5.7(5.0,6.5)
26.7(23.9,29.5) 17.8(16.0,19.5) 6.1(4.8,7.3)
29.8(27.3,32.4) 22.4(18.2,26.7) 8.9(7.3,10.5)
36.6(29.7,43.5) 18.2(15.7,20.8) 8.4(6.4,10.4)
31.7(26.9,36.4) 21.8(17.6,26.1) 6.4(3.5,9.3)
28.4(25.3,31.5) 18.3(15.1,21.6) 10.6(8.1,13.2)
29.9(25.9,34.0) 26.2(18.2,34.2) 10.7(7.8,13.5)
36.7(29.7,43.7) 16.4(13.8,19.1) 8.8(6.5,11.1)
28.7(22.7,34.8) 23.0(15.6,30.4) 5.5(2.6,8.5)
27.2(24.3,30.0) 25.1(19.1,31.0) 12.6(9.4,15.7)
32.7(31.0,34.5) 17.8(16.1,19.5) 7.7(6.5,8.8)
25.3(22.0,28.6) 17.3(13.7,21.0) 2.3(1.6,3.0)
29.7(26.8,32.5) 18.6(16.4,20.9) 7.1(5.6,8.6)
36.5(28.9,44.0) 20.0(16.3,23.8) 8.0(5.6,10.4)
33.9(27.9,39.9) 20.9(16.4,25.4) 7.1(2.6,11.6)
30.2(27.8,32.5) 21.5(18.1,24.9) 6.8(5.0,8.7)
28.7(26.9,30.6) 16.1(14.2,17.9) 4.0(3.2,4.8)
ycerides ≥ 150 mg/dL [1.7 mmol/L], LDL cholesterol ≥ 130 mg/dL [3.4 mmol/L], or HDL
rent cholesterol-loweringmedication use), hypertension (SBP ≥ 140mmHg and/or DBP ≥
ose ≥ 7.0 mmol/L [126 mg/dL] or HbA1c concentration of 6.5% or more and/or current
).
5F. Yang et al. / Clinical Trials and Regulatory Science in Cardiology 15 (2016) 1–6but the prevalence of subjects having ≥1 and ≥2 CVD risk factorsmay be
slightly lower than in the U.S.
In our study, ﬁndings on differences between subgroups in CVD risk
factors prevalence have been consistent with the previous studies [11,
12]. The reason of difference between urban and rural areas may be
associated with the distribution of some risk factors (diet and lifestyle).
Higher intake in dietary lipids and alcohol, and lower physical activity
are a few of the lifestyle behaviors that were associated with urbaniza-
tion Refs. [26–28] might also help explain this regional disparity. And
elderly is high-risk population of CVD so we need to pay special
attention to this high-risk population on precaution of the CVD risk
and improving the prognosis.
This study had several limitations. First, the survey sampleswere the
persons 45 years of age and older that did not include elderly residents
in nursing homes because there is very small proportion of residents
living in nursing-home in China [13].
This study indicates that clustering of CVD risk factors was a high
health burden in the Chinese middle aged and elderly population.
These results indicate that, given its large population affected CVD risk
factors and the high-risk of CVD, we may bear a higher CVD risk factors
related burden and underscore the need for strategies aimed at the
prevention, detection, and treatment of CVD factors to reducemorbidity
and mortality from CVD.
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